Mirikizumab
Mirikizumab (INN;[1] development code LY3074828) is a human monoclonal antibody designed for the treatment of psoriasis.
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | interleukin 23A |
Clinical data | |
Other names | LY3074828 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6380H9842N1686O2004S48 |
Molar mass | 143767.59 g·mol−1 |
This drug was developed by Eli Lilly and Co.[2] As of 2018, mirikizumab is undergoing Phase III trials.
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.